drugset / Trial / NCT02987920

Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty

NCT02987920

Phase 4 Terminated 23 enrolled University of Southern California
RandomizedParallel-groupTriple-blindTreatment

Summary

Total knee arthroplasty (TKA) is one of the most painful orthopedic procedures. After TKA surgery, postoperative pain relief may be achieved using a variety of techniques. Integral to recovery and improved outcomes is early ambulation and mobilization. Achieving adequate postoperative pain control while ensuring the ability to ambulate early can be quite challenging. Currently, in our country there has been a call to address prescription opioid use and abuse due to a nationwide opioid epidemic. In light of this, improving our multimodal analgesic protocol will serve to decrease reliance of opioid medications for pain control. Multimodal analgesia is effective in decreasing total opioid consumption postoperatively. Dextromethorphan is a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. It has a long history of clinical use with an established safety record. Studies have shown that it has a positive effect as an analgesic. In order to see if dextromethorphan will decrease opioid use, this study will look at two patient groups undergoing total knee arthroplasty with the same preoperative, intraoperative, and postoperative anesthetic plan with the exception of the addition of dextromethorphan to one groups multimodal analgesic regimen. This study is designed as a double-blinded, randomized, prospective cohort trial.

Timeline

Start
2017-01
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 60 mg Oral
Background Acetaminophen Small molecule 1000 mg Oral
Background Celecoxib Other / unclassified 400 mg Oral
Background Gabapentin Small molecule 100 mg Oral
Background Gabapentin Small molecule 300 mg Oral
Background Hydromorphone Other / unclassified 0.2 mg Intravenous
Background Hydromorphone Other / unclassified 2 mg Intravenous
Background Ketorolac Other / unclassified 15 mg Intravenous
Background Ketorolac Other / unclassified 30 mg Intravenous
Background Oxycodone Other / unclassified 5 mg Oral
Background Oxycodone Other / unclassified 10 mg Oral
Background Pantoprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.